A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Inclusion criteria: * Quantifiable serum hepatitis C virus-ribonucleic acid (HCV-RNA) * Hepatitis C virus genotype 1 * Homeostasis Model of Assessment - Insulin Resistance (HOMA IR) \> 2.5 in two determinations made 4 weeks apart (the first HOMA evaluation is able to be made 3 weeks before screening visit) * Previous failure to achieve SVR with PegIFN plus ribavirin given for a minimum of 12 weeks without dose reduction below 80% of the adequate doses of the two drugs * No response, partial response, or relapse after previous therapy * Compensated liver disease with or without histologic or non-invasive evidence of liver cirrhosis * If heterosexually active, a female participant of childbearing potential and a non-vasectomized male participant who has a female partner of childbearing potential must agree to use 2 effective contraceptives until 6 months after therapy has ended (7 months for male subject) Exclusion criteria: * Coinfection with HCV genotypes other than HCV-GT1 * Evidence of decompensated liver disease * History of ascites, hepatic encephalopathy or of bleeding varices or severe portal hypertension * History or signs or symptoms or evidence of hepatocellular carcinoma (HCC) * History of organ transplant * Coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) * Severe psychiatric disease * Inadequately controlled thyroid function * Other important comorbidities (cardiovascular diseases, Type 1 diabetes or inadequately controlled type 2 diabetes, malignancies , etc) * Substances abuse * Alcohol intake \>20 grams/day for females and \>30 grams/day for males * History of severe adverse events during previous treatment with PegIFN plus ribavirin including discontinuation of therapy for severe anemia or hematologic toxicity